Parmax Pharma EGM: All 4 resolutions pass, preferential issues approved
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
EGM held July 2, 2026 with 4 resolutions, all passed. Approved: (1) increase in authorized share capital and MOA change; (2) new Articles of Association; (3) preferential issue of 31,37,586 equity shares to non-promoters; (4) 21,45,145 convertible warrants to non-promoters. Combined voting saw 23,36,153 votes polled (about 62 percent of 37,41,300 total shares), with virtually 100 percent in favour across all resolutions. Filing is a resubmission adding Chairman counter-signature, with no changes to results.
Major dilution risk: combined preferential equity and warrants equal roughly 141 percent of existing share base, which may weigh on the stock and reduce promoter holding.